Houston Oncology Summit
- October 17, 2019
Please join us for our Oncology Summit in Houston, TX on Thursday, October 17, 2019 featuring faculty members from MD Anderson Cancer Center. The day will consist of lectures by notable scientists and researchers at MD Anderson and presentations from select oncology companies.
In addition, we will be featuring The Checkmates, a band of top MD Anderson surgeons and executives. The live performance will be raising funds for MD Anderson Children’s Cancer Hospital, and we are excited to be partnering with this institution to help further the fight against cancer.
Conferences are only open to established institutional clients of Oppenheimer & Co. Inc.
For more information, please contact your Oppenheimer & Co. Inc institutional sales representative.
Featured Discussions with
MD Anderson Faculty Members
Associate Professor, Department of Surgical Oncology & Department of Genomic Medicine
Jennifer A. Wargo, M.D., M.MS.c. has significantly contributed to the knowledge of resistance mechanisms and the effect of targeted therapy on anti-tumor immunity. She joined MD Anderson in September 2013 to build a program collecting serial biopsies in patients, particularly those with melanoma, being treated with chemotherapy, targeted therapy and immunotherapy. The goal of this program is to better understand responses to therapy and develop novel strategies to combat resistance.
Currently, her team is examining the microbiome — the collective population of microorganisms that live in and on humans — to determine the role it plays in patient response to cancer therapy.
VP, Therapeutics Discovery, Institute for Applied Cancer Science (IACS)
Philip Jones, Ph.D., is a drug hunter that leads a multi-disciplinary team of scientists whose mission is to identify the next generation of cancer medicines, move those into clinical trials and hopefully into clinical practice. Developing medicines is a challenging process, and engineering all the necessary properties for a single molecule to be effective in patients requires collaboration and team work across many disciplines. Jones is fortunate to work with a high-performance team, who has already delivered a drug into trials at MD Anderson since its inception. His team also has a number of promising programs coming along behind.
Professor, Department of Stem Cell Transplantation
Director of Translational Research
The Rezvani laboratory broadly focuses on the role of natural killer (NK) cells in mediating protection against hematologic malignancies and solid tumors and strategies to enhance killing function against various cancer.
Associate Professor, Department of Clinical Cancer Prevention
Dr. Vilar-Sanchez is a physician-scientist and a medical oncologist by training. Dr. Vilar’s clinical expertise and practice are devoted to the care of patients and families diagnosed with hereditary cancer syndromes with a special emphasis in Lynch Syndrome and Familial Adenomatous Polyposis. His long term goal is to contribute to the understanding of colorectal cancer carcinogenesis at the molecular and cellular level and leverage this information to develop novel cancer interception strategies for these genetic conditions.
Associate Professor, Department of Melanoma Medical Oncology
Director of Melanoma Clinical Research and Early Drug Development
Dr. Tawbi's research interests include mechanisms of resistance to therapy in melanoma, melanoma brain metastase, Epigenetic regulation of therapeutic resistance, and drug development and early phase clinical trials.
Director, Research Planning & Development, Surgical Oncology
Elizabeth (Liz) serves as the project director for the Melanoma Moon Shot™ and its high-priority projects including basic and translational research projects, clinical research, behavioral science interventions and legislative/policy initiatives.